Celularity Inc. (CELU) Stock Forecast
Data as of May 3, 2026Healthcare · Current price $0.96 (+2.78%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Aug 23, 2022 | Asthika Goonewardene | Truist Financial | $3.00 | +212.4% |
Top Analysts Covering CELU
CELU vs Sector & Market
| Metric | CELU | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | — | 2.24 | 2.41 |
| Analyst Count | — | 8 | 18 |
| Target Upside | +212.4% | +1150.0% | +14.9% |
| P/E Ratio | -0.34 | 6.87 | 31.19 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $44M | $44M | $44M | 1 |
| 2027-12-31 | $286M | $286M | $286M | 1 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $-2.75 | $-2.75 | $-2.75 | 1 |
| 2027-12-31 | $1.50 | $1.50 | $1.50 | 1 |
Frequently Asked Questions
What is the analyst consensus for CELU?
The consensus among 0 analysts covering Celularity Inc. (CELU) is — with an average price target of $3.00.
What is the highest price target for CELU?
The highest price target for CELU is $3.00, set by Asthika Goonewardene at Truist Financial on 2022-08-23.
What is the lowest price target for CELU?
The lowest price target for CELU is $3.00, set by Asthika Goonewardene at Truist Financial on 2022-08-23.
How many analysts cover CELU?
0 analysts have issued ratings for Celularity Inc. in the past 12 months.
Is CELU a buy or sell right now?
Based on 0 analyst ratings, CELU has a consensus rating of — with a +212.4% upside to the consensus target of $3.00.
What are the earnings estimates for CELU?
Analysts estimate CELU will report EPS of $-2.75 for the period ending 2026-12-31, with revenue estimated at $44M.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.